Barclays’s Neuphoria Therapeutics NEUP Stock Holding History

Barclays’s Portfolio NEUP Stock Details NEUP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$11	Buy	+3	New	+$11	﹤0.01%	5172

Other funds holding NEUP

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Barclays's NEUP Position: Q3 2026 in Review

Barclays opened a new position in Neuphoria Therapeutics (NEUP) in Q3 2026: 3 shares worth $11. The stake represents ﹤0.01% of the portfolio and ranks #5172 among its holdings.

2 funds tracked by Wall St. Rank hold NEUP as of Q3 2026.

Barclays held 3 shares of Neuphoria Therapeutics worth $11 as of Q3 2026.
Neuphoria Therapeutics was a new Barclays position in Q3 2026.
Neuphoria Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #5172 holding.
2 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.